Press Releases

Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

Everest Medicines' Partner Calliditas Announces an Additional Efficacy Analysis of NEFECON® at the 61st European Renal Association Congress

Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China

Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau

Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients

Everest Medicines’ Partner Calliditas Announces Positive NefIgArd Open Label Extension Results

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023

Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

Everest Medicines’ Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®

Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau

Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Everest Medicines’ Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

Everest Medicines’ Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam’s Phase 3 CERTAIN-1 Study in New England Journal of Medicine

Everest Medicines Announces Termination of Collaboration Agreements with Providence

Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million

Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients

Everest Medicines’ Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline

Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China